As shown in Table 2, downregulation of CTSG in HNSC was significantly associated with the primary therapy outcome (p = 0.003), race (p = 0.044), anatomic neoplasm subdivision (p = 0.005), and overall survival (p = 0.015). This evidence concerns the gene CTSG and neoplasm.